Archive for September, 2016

$GWRS Declares Monthly #Dividend

PHOENIX, Ariz., Sept. 30, 2016  — Global Water Resources, Inc. (NASDAQ:GWRS), (TSX:GWR), a pure-play water resource management company, has declared, under its dividend policy, a monthly cash dividend in the amount of $0.022 per common share (an annualized amount of $0.264 per share), which will be payable on October 31, 2016, to holders of record at the close of business on October 17, 2016.

About Global Water Resources, Inc.
Global Water Resources, Inc. is a comprehensive water resource management company based in Phoenix, Arizona. It manages the entire water cycle by owning and operating water, wastewater and recycled water utilities. For more information about Global Water Resources, visit www.gwresources.com.

Company Contact for Global Water Resources
Michael J. Liebman 
Chief Financial Officer and Corporate Secretary 
(480) 999-5104 
mike.liebman@gwresources.com

Investor Relations for Global Water Resources:
Ronald A. Both
Liolios Investor Relations
(949) 574-3860
gwrs@liolios.com
Friday, September 30th, 2016 Uncategorized Comments Off on $GWRS Declares Monthly #Dividend

$CQH #Buyout Offer by $LNG

HOUSTON, Sept. 30, 2016  — Cheniere Energy Partners LP Holdings, LLC (“Cheniere Partners Holdings”) (NYSE MKT: CQH) announced today that its board of directors has received a proposal from Cheniere Energy, Inc. (“Cheniere”) (NYSE MKT: LNG) pursuant to which Cheniere would acquire the publicly held shares of Cheniere Partners Holdings not already owned by Cheniere in a stock for stock exchange. Subject to negotiation and execution of a definitive agreement, Cheniere is proposing consideration of 0.5049 Cheniere shares for each issued and outstanding publicly-held share of Cheniere Partners Holdings as part of a transaction that would be structured as a merger of Cheniere Partners Holdings with a wholly-owned subsidiary of Cheniere. The proposed consideration represents a value of $21.90 per common share of Cheniere Partners Holdings, or a premium of approximately 3.0% over the closing price of Cheniere Partners Holdings’ shares, based on the closing prices of Cheniere Partners Holdings’ shares and of Cheniere’s shares as of September 29, 2016, or a premium of approximately 7.0% over the 30-trading day average CQH / LNG exchange ratio as of September 29, 2016.

Cheniere owns 80.1% of the issued and outstanding shares of Cheniere Partners Holdings.

The proposed transaction is subject to the negotiation and execution of a definitive agreement and approval of such definitive agreement and transactions contemplated thereunder by the board of directors of Cheniere, the board of directors of Cheniere Partners Holdings and a conflicts committee established by the board of directors of Cheniere Partners Holdings, and the consummation of the proposed transaction would be subject to customary closing conditions. There can be no assurance that any such approvals will be forthcoming, that a definitive agreement will be executed or that any transaction will be consummated.

About Cheniere Partners Holdings

Cheniere Partners Holdings owns a 55.9% limited partner interest in Cheniere Energy Partners, L.P. (NYSE MKT: CQP) (“Cheniere Partners”), a publicly traded limited partnership. Cheniere Partners Holdings’ only business consists of owning Cheniere Partners units and, accordingly, its results of operations and financial condition are dependent on the performance of Cheniere Partners. Cheniere Partners owns and operates liquefied natural gas (“LNG”) regasification facilities and, adjacent to these facilities, plans to construct over time up to six natural gas liquefaction trains (“Trains”) with an expected aggregate nominal production capacity of approximately 27 mtpa. Trains 1 and 2 have achieved substantial completion. Train 3 is undergoing commissioning, Trains 4 and 5 are under construction, and Train 6 is fully permitted.

For additional information, please refer to the Cheniere Partners Holdings website at www.cheniere.com and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the Securities and Exchange Commission.

Forward-Looking Statements

This press release includes “forward-looking statements”. In particular, statements using words such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology generally involve forward-looking statements. The forward-looking statements contained herein (including statements regarding the proposed transaction and its effects, benefits and costs, savings, opinions, forecasts, projections, expected timetable for completion, expected distribution, and any other statements regarding Cheniere Partners Holdings’ and Cheniere’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not statements of historical fact) are largely based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe that such estimates are reasonable, they are inherently uncertain and involve a number of risks and uncertainties beyond our control. In addition, assumptions may prove to be inaccurate. We caution that the forward-looking statements contained herein are not guarantees of future performance and that such statements may not be realized or the forward-looking statements or events may not occur. Actual results may differ materially from those anticipated or implied in forward-looking statements as a result of numerous factors, including, but not limited to, the negotiation and execution, and the terms and conditions, of a definitive agreement relating to the proposed transaction and the ability of Cheniere or Cheniere Partners Holdings to enter into or consummate such an agreement; the risk that the proposed merger does not occur; negative effects from the pendency of the proposed merger; the ability to realize expected cost savings and benefits; failure to obtain the required vote of Cheniere Partners Holdings’ shareholders; the timing to consummate the proposed transaction; the impact of regulatory changes; and other factors affecting future results disclosed in Cheniere’s and Cheniere Partners Holdings’ respective filings with the SEC (available at the SEC’s website at www.sec.gov), including but not limited to those discussed under Item 1A, “Risk Factors”, in Cheniere’s Annual Report on Form 10-K for the year ended December 31, 2015 and Cheniere Partners Holdings’ Annual Report on Form 10-K for the year ended December 31, 2015. These forward-looking statements speak only as of the date made, and other than as required by law, we undertake no obligation to update or revise any forward-looking statement or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of a proxy or of any vote or approval. This communication may be deemed to be solicitation material in respect of the proposed transaction between Cheniere and Cheniere Partners Holdings. In the event that the parties enter into a definitive agreement with respect to the proposed transaction, the parties intend to file a registration statement on Form S-4, containing a proxy statement/prospectus (the “S-4”) with the SEC. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Cheniere or Cheniere Partners Holdings may file with the SEC or send to shareholders in connection with the proposed transaction. INVESTORS AND SHAREHOLDERS OF CHENIERE PARTNERS HOLDINGS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT/PROSPECTUS IF AND WHEN FILED, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

When available, investors and security holders will be able to obtain copies of the S-4, including the proxy statement/prospectus and any other documents that may be filed with the SEC in the event that the parties enter into a definitive agreement with respect to the proposed transaction free of charge at the SEC’s website at http://www.sec.gov. Copies of documents filed with the SEC by Cheniere will also be made available free of charge on Cheniere’s website at www.cheniere.com. Copies of documents filed with the SEC by Cheniere Partners Holdings will also be made available free of charge on Cheniere Partners Holdings’ website at www.cheniere.com.

Participants in the Solicitation

Cheniere, Cheniere Partners Holdings and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies from Cheniere Partners Holdings’ shareholders with respect to the proposed transaction. Information about Cheniere Partners Holdings’ directors and executive officers is set forth in Cheniere Partners Holdings’ 2015 annual report on Form 10-K, which was filed with the SEC on February 19, 2016, and in Cheniere Partners’ Holdings current reports on Form 8-K, which were filed with the SEC on May 12, 2016, June 6, 2016, and September 19, 2016. Information about Cheniere’s directors and executive officers is set forth in Cheniere’s proxy statement for its 2016 Annual Meeting of Shareholders, which was filed with the SEC on April 21, 2016, and in Cheniere’s current reports on Form 8-K, which were filed with the SEC on May 12, 2016, June 6, 2016, and September 19, 2016. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction if and when they become available. Investors should read the proxy statement/prospectus carefully if and when it becomes available before making any voting or investment decisions.

CONTACTS:

Investors: Randy Bhatia: 713-375-5479
Media: Faith Parker: 713-375-5663

Friday, September 30th, 2016 Uncategorized Comments Off on $CQH #Buyout Offer by $LNG

$ASCMA Monitronics Rebrands as #MONI Begins New Era Of Smart #HomeSecurity

New Name Reflects the Company’s Evolution as a Smart Home Security Solutions Organization with Faster, More Personalized Offerings

DALLAS, Sept. 30, 2016  — Monitronics, a subsidiary of Ascent Capital Group, Inc. (Nasdaq: ASCMA) today unveiled its new name: “MONI,” beginning a new era of smart home security that brings increased speed and personalization to the market.

The Company has been the “secret sauce” behind more than 600 independent alarm companies’ successes for the past two decades, with a cutting-edge monitoring solution that secures more than one million residential customers and commercial client accounts in the US.  However, “Monitronics” was intentionally unbranded in the eyes of the consumer, allowing independent dealer brands to take center stage. The new MONI brand will be marketed directly to consumers and supported by direct-to-consumer sales and customer support. This will not only enable MONI’s expert custom solutions to flow directly into the home, but is designed to nurture MONI’s trusted dealer network by showing consumers the strength behind the individual dealer brands. The new branding will also provide dealers with the national marketing, sales and customer service support that they need to compete more effectively in their regional markets.

“As a leader in home security solutions for more than 20 years, professionally installed and monitored smart home security has always remained at the core of our business,” said Jeff Gardner, president and CEO of MONI. “Home and business security needs are as unique and individualized as each customer. Solution offerings and customer service throughout the industry must change as we enter a new era of smart home security that emphasizes a customized approach to comprehensive safety and protection.”

MONI sees the new era of smart home security as one where personal safety takes priority in the connected home. This is enabled by:

  • Simplified “Smart” Homes
    • Delivering leading products that integrate with existing systems and packages, enabling mainstream home automation features that emphasize complete security and control
  • Customer-Centric Personalization
    • Personalized solutions that are truly tailored to the needs of each individual consumer, allowing them to customize not only equipment and services, but the entire customer experience for greater control, confidence and security
  • Faster Response
    • Faster response times to alarm events – managing the personal and home security concerns that matter most in seconds for true peace of mind

“Whether it is a routine situation or lives are on the line, MONI knows that every moment matters,” continued Gardner. “Over the last two decades we have built our business on the ability to listen and respond. Customers have spoken, and they are calling for a new approach to smart home security, a new era of customer-centric personalization with solutions designed to meet the needs of each individual, and MONI is poised to deliver.”

To learn more about MONI and the full suite of personalized security solutions available, visit www.mymoni.com.

About MONI
MONI, the new Monitronics, is a subsidiary of Ascent Capital Group, Inc. (NASDAQ: ASCMA) and is one of the largest home security alarm monitoring companies in the U.S. Headquartered in the Dallas Fort-Worth area, MONI secures more than one million residential customers and commercial client accounts with monitored home and business security system services. The company is supported by the nation’s largest network of independent Authorized Dealers, providing products and support to customers in the U.S., Canada and Puerto Rico.

Contact: Lindsay Lougee
MONI Smart Security
Tel: 972-243-7443, ext. 73121
E-mail: llougee@mymoni.com

Friday, September 30th, 2016 Uncategorized Comments Off on $ASCMA Monitronics Rebrands as #MONI Begins New Era Of Smart #HomeSecurity

$SVVC Portfolio Company #Nutanix Goes Public

SAN JOSE, Calif., Sept. 30, 2016  — Firsthand Technology Value Fund, Inc. (NASDAQ:SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today that Nutanix, a Fund holding since May 2015, went public today through an initial public offering (“IPO”). The IPO was priced last evening at $16.00 per share, resulting in proceeds to the company of approximately $238 million. The shares, which now trade on the NASDAQ under the ticker symbol “NTNX”, opened their first day of trading at $26.50.

“In what has been a challenging environment for tech IPOs, we are excited about the successful public debut for Nutanix,” stated Kevin Landis, Firsthand’s CEO.  “This marks the 7th IPO for our fund since its inception in 2011 and follows the successful exits of Mattson and Tapad earlier this year.”

The Fund holds 459,772 shares of Nutanix common stock as of September 30, 2016, at an approximate average cost of $16.04 per share. The Fund’s shares are subject to a customary 180-day lockup provision.

Nutanix is a provider of so-called “hyperconverged” data center equipment that merges computing, storage, and networking capabilities in a single piece of equipment. The company’s products offer corporate customers access to technologies similar to those used by Google, Amazon, and Facebook in their own data centers.

About Firsthand Technology Value Fund
Firsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies. More information about the Fund and its holdings can be found online at www.firsthandtvf.com.

The Fund is a non-diversified, closed-end investment company that elected to be treated as a business development company under the Investment Company Act of 1940. The Fund’s investment objective is to seek long-term growth of capital. Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies.  An investment in the Fund involves substantial risks, some of which are highlighted below.  Please see the Fund’s public filings for more information about fees, expenses and risk.  Past investment results do not provide any assurances about future results.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined under the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to materially differ from the Fund’s historical experience and its present expectations or projections indicated in any forward-looking statement. These risks include, but are not limited to, changes in economic and political conditions, regulatory and legal changes, technology and cleantech industry risk, valuation risk, non-diversification risk, interest rate risk, tax risk, and other risks discussed in the Fund’s filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Fund undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Fund’s investment objectives will be attained. We acknowledge that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as us.

Contact:

Heather Hohlowski
Firsthand Capital Management, Inc. 
(408) 624-9525
vc@firsthandtvf.com
Friday, September 30th, 2016 Uncategorized Comments Off on $SVVC Portfolio Company #Nutanix Goes Public

$ITUS Demonstrates Efficacy of #Cchek in #Ovarian #Cancer

LOS ANGELES, CA–(September 30, 2016) – ITUS Corporation (“ITUS“) (NASDAQ: ITUS), today announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Ovarian Cancer. There is currently no sufficiently accurate test for the early detection of Ovarian Cancer, which has a 5-year survival rate of only 46%.

Cchek™ is ITUS’s early cancer detection technology which measures a patient’s immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of the ongoing development of ITUS’s Cchek diagnostic platform, the company has successfully used Cchek to detect the presence of Ovarian Cancer in patients that have been diagnosed via conventional means such as invasive procedures like surgical biopsies.

Approximately 250,000 new cases of Ovarian Cancer are diagnosed each year worldwide, and Ovarian Cancer causes approximately 140,000 deaths. Overall, only 15% of Ovarian Cancer cases are diagnosed at a local stage, for which the 5-year survival rate is 92%. The company previously announced success with Cchek detecting Breast Cancer, Lung Cancer, Colorectal Cancer and Melanoma.

ITUS Corporation
ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body’s immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

Contact:
Dean Krouch
310-484-5184
dkrouch@ITUScorp.com

Friday, September 30th, 2016 Uncategorized Comments Off on $ITUS Demonstrates Efficacy of #Cchek in #Ovarian #Cancer

$EFOI Fixtures Qualified for #USNavy Use on New Ships

Entire family of 2-ft Tubular LEDs and fixtures are first competitive choice for Navy in nearly 70 years

SOLON, Ohio, Sept. 29, 2016  — Energy Focus, Inc. (NASDAQ:EFOI), a leader in LED lighting technologies, today announced that the U.S. Navy Naval Sea Systems Command has qualified the entire family of Energy Focus 2-ft. tubular LEDS (TLEDs) and fixtures for use on new ship construction. Approval of the single-, double- and triple-tube 2-ft. fixtures was granted on Sept. 22.

“For nearly 70 years, new vessel development has depended on only one manufacturer for fixtures,” said Dave Bina, Energy Focus Senior Vice President of Military and Maritime Sales. “Now, new ships will have a competitive choice between the legacy standards and Energy Focus’ cutting-edge LED lighting technology.”

Since 2007, when Energy Focus became the first company to develop, qualify and install LED products on Navy vessels, Energy Focus has provided LED lighting for every surface ship in the fleet. Through this partnership, Energy Focus has developed, qualified and installed more than a half-million LED lighting products, including TLEDs, floodlights, waterline security lights, HAZLOC globes and berth lights, on U.S. Navy vessels.

In the military, there is a constant need to go farther, stay longer and deliver more firepower. Energy Focus contributes to this need as the premier supplier to the U.S. Navy for qualified LED lighting for the fleet. Compared to legacy manufacturer’s LED fixtures, Energy Focus LEDs consume one-third less energy and weigh 25-percent less. On a ship with thousands of light fixtures, Energy Focus fixtures could save significant unnecessary weight on the vessels that protect American interests around the world.

“We are very pleased to have received another critical recognition from the U.S. Navy to enable us to serve the LED lighting needs for new Navy ships,” said James Tu, CEO and President of Energy Focus. “This new family of LED lighting fixtures, with extremely competitive value proposition from quality, performance and price standpoints, will be able to address new ship construction segments of not only U.S. and foreign allied navies but also the broader commercial marine market.”

About Energy Focus, Inc. 

Energy Focus, Inc. is a leading provider and innovator of energy efficient LED lighting products. As the creator of the only 100-percent flicker-free LED products on the market, Energy Focus products provide extensive energy savings, aesthetics, safety and health benefits over conventional and fluorescent lighting. As a long standing partner with the US Government providing energy efficient LED lighting products to the U.S. Navy and the Military Sealift Command fleets, Energy Focus products go through rigorous testing in the most adverse conditions possible and still have a zero percent failure rate. In the commercial sphere, customers include national, state and local U.S. government agencies as well as Fortune 500 companies across education, healthcare, retail and manufacturing. Energy Focus is headquartered in Solon, Ohio, with additional sales offices in Washington, D.C., New York and Taiwan.

Media Contact:
Michael Miller
Content Strategist
Energy Focus, Inc.
msmiller@energyfocusinc.com
(440) 715-1300 Office
(734) 945-6359 Cell

Investor Contact:
Darrow Associates, Inc.
Peter Seltzberg
pseltzberg@darrowir.com
516-419-9915
Thursday, September 29th, 2016 Uncategorized Comments Off on $EFOI Fixtures Qualified for #USNavy Use on New Ships

$ABUS Interim Results #Phase2 #ClinicalTrial of #ARB1467 in #HBV

  • Single Dose Data Demonstrate Significant Reduction in Serum HBsAg
  • Additive Reductions in Serum HBsAg Observed with Repeat Dosing over 3 Months
  • 5 of 6 Patients in Cohort 1 Had Serum HBsAg Reductions of Greater Than 0.5 log10 After 3 Doses
  • Additional Multi-Dose ARB-1467 Data Expected in 4Q16
  • Company to Host Conference Call Today at 5 pm ET to Discuss Results

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 29, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today reported interim results from the first two cohorts of the ongoing ARB-1467 Phase II multi-dose clinical trial in chronically infected HBV patients.  The first two cohorts enrolled patients with hepatitis B e-antigen (HBeAg) negative chronic HBV infection. At this time, serum HBsAg data are available following single doses for both Cohort 1 and Cohort 2 and following multiple doses for Cohort 1.

Single dose ARB-1467 results for Cohorts 1 and 2 demonstrate significant reductions in serum HBsAg levels. Importantly, multiple dose results from Cohort 1 show a step-wise, additive reduction in serum HBsAg. These multiple dose results are the first of their kind for an RNAi product candidate in patients with chronic HBV infection. Treatment with ARB-1467 has been generally well tolerated to date.

      Single Dose HBsAg Reduction
(log10 IU/mL)
Multiple Dose HBsAg Reduction
(log10 IU/mL)
Cohort N  ARB-1467
(mg/kg)
 Mean  Mean Maximum  Maximum  Mean  Mean Maximum  Maximum
1 6 0.2 -0.3 -0.4 -1.0 -0.6 -0.7 -1.3
2 6 0.4 -0.2 -0.3 -0.8 NA NA NA
 Placebo  4 0.0 0.0 -0.1 0.0 0.0 -0.1
aThe mean serum HBsAg reduction is the nadir value of the arithmetic mean of all values observed at each time point.
bThe mean maximum HBsAg reduction is the mean of each patient’s maximum reduction in serum HBsAg.
cMaximum HBsAg reduction is the best single reduction among all patients in a cohort.
dSingle dose placebo results are based on four subjects (two from each cohort). Multiple dose placebo results are based on the two placebo subjects in Cohort 1.

“The interim ARB-1467 data demonstrate significant serum HBsAg reduction following the first dose, which is enhanced with repeat dosing. This is a very important finding because it suggests that even greater reductions in serum HBsAg levels may be observed with continued dosing of ARB-1467,” said Dr. Douglas T. Dieterich, Professor of Medicine in the Division of Liver Disease at Icahn School of Medicine at Mount Sinai Medical Center. “These exciting data demonstrate the antiviral effect of ARB-1467 and the potential to include this agent as a component of a combination therapy regimen for the treatment of chronic HBV infection.”

“We are excited about these HBV efficacy data from our ongoing ARB-1467 Phase II trial demonstrating substantial reductions in serum HBsAg, which is an important first step towards one day curing chronic HBV infection. We believe that further study of ARB-1467 will help determine the optimal protocol to produce maximal reductions in serum HBsAg,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “We plan to release additional multi-dose data later this year. We believe that ultimately curing HBV will require combination therapy and we are developing a portfolio of HBV assets with complementary mechanisms of action to accomplish this goal.”

ARB-1467 Phase 2 Trial Design
The Phase II trial is a multi-dose study in chronic HBV patients who are also receiving stable nucleot(s)ide analog therapy. The trial consists of three cohorts, each enrolling eight subjects; six receiving three monthly doses of ARB-1467, and two receiving placebo. The first two cohorts include HBeAg- patients, followed by a third cohort in HBeAg+ patients.

About ARB-1467
Arbutus’ RNAi candidate ARB-1467 comprises three RNAi triggers that target all four HBV transcripts, and has been shown in preclinical studies to reduce all viral antigen levels as well as cccDNA and HBV DNA.  ARB-1467 utilizes Arbutus’ proprietary lipid nanoparticle (LNP) platform, a clinically validated delivery technology which has been tested in hundreds of patients.

Conference Call Today
Arbutus will hold a conference call and webcast today, September 29, 2016, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide interim results from the ongoing ARB-1467 Phase II clinical trial. A live webcast of the call can be accessed through the Investor section of Arbutus’ website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 91182747.

About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.  Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.

Forward Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about possibly even greater reductions in serum HBsAg levels with continued dosing of ARB-1467; the potential to include ARB-1467 as a component of a combination therapy regimen for the treatment of chronic HBV infection; determining the optimal protocol to produce maximal reductions in serum HBsAg through further study of ARB-1467; releasing additional multi-dose data later this year; and developing a portfolio of HBV assets to ultimately cure HBV through combination therapy.

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K and Arbutus’ continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information 
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200 
Email: acutler@arbutusbio.com

Helia Baradarani
Senior Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com

Media
Please direct all media inquiries to: media@arbutusbio.com
Thursday, September 29th, 2016 Uncategorized Comments Off on $ABUS Interim Results #Phase2 #ClinicalTrial of #ARB1467 in #HBV

$NXPI Delivers Enhanced Anti-Cloning Security Solution

NXP adds PUF Anti-Cloning technology to its next generation SmartMX2 microcontroller enabling electronic identification solutions to thrive in the age of Smart Cities

EINDHOVEN, Netherlands, Sept. 29, 2016  — NXP Semiconductors N.V. (NASDAQ:NXPI) today unveiled its next generation of SmartMX2 P60 Step-Up! that offers customers unique security features such as PUF (Physical Unclonable Function) anti-cloning technology for higher encryption key protection.

Today, many Smart City initiatives seek to make urban living simpler, safer and healthier. These initiatives drive greater demand for secure technologies to protect individual and financial credentials. To address this demand, NXP’s new SmartMX2 P60 Step-Up! Secure Element provides secure authentication and confidential data exchange.

To be first in market in smart cards, NXP is collaborating with MaskTech, the leading independent provider of high security smart card operating systems for electronic identification cards, travel documents and authentication solutions. Together, the companies will add PUF anti-cloning technology to secure smart cards for applications like ePassports, eID cards, driving licenses, health cards, payment cards and embedded security.

“Security and convenience for smart city solutions are of paramount importance,” said Managing Director at MaskTech, Dr. Hans Hanauer. “By adding the support for the PUF feature in the new MTCOS version, MaskTech stays at the leading edge of high security smart card technology. PUF is a completely new technology for the protection of credentials. We’re pleased to work with NXP, the leader in secure identification solutions, to deliver these smarter cards into the market.”

“NXP has a relentless commitment to develop state-of-the art products that meet the high-end security requirements for sensitive applications like payment, e-government and access management,” said Sébastien Clamagirand, Senior Director and General Manager Secure Identification at NXP. “Seeing the first roll-out of SmartMX with PUF technology is a great milestone and addresses the market need for high secure identification solutions.”

SmartMX2 P60 Step-Up!
The latest SmartMX2 generation builds on the groundbreaking IntegralSecurityTM architecture and includes a series of new security enhancements:

  • PUF support to secure the keys against new attack scenarios via unique “silicon fingerprint” with each single circuit
  • Hardware-support for dedicated cryptography in certain regions: SEED (Korea), OSSCA (China)
  • End-to-end encryption, AES and DES coprocessors for high resistance to side-channel attacks
  • Mature Development Tool kit SmartICE based on a true Bondout Chip with identical-to-product hardware for a safe and application-compliant implementation with full planning reliability
  • Soft Masking Device for early functional prototypes based on identical-to-product hardware to reduce the development cycle time via an approved physical reference instance
  • Full amount of SmartMX2 security features, including NXP-patented SecureFetch and GlueLogic for optimum relief of operation system countermeasures and safe and fast composite certifications and approvals.

The new SmartMX2 platform also received comprehensive 3rd party recognition:

  • Common Criteria EAL6+ certificate (EAL 5+ with MIFARE and/or DESFire EV1 inclusion)
  • EMVCo Approval
  • UL Letter of Conformance for MIFARE functionality

About the SmartMX Family
SmartMX, the platform of choice for high secure and fast data transactions, is a proven solution for contact, contactless and dual interface applications with over 6 billion IC´s sold. Serving banks all over the world, from Shanghai to London and New York to Berlin, NXP’s SmartMX secures transactions on over one third of the chip-based payment cards in circulation. NXP’s SmartMX products are also the core component in a variety of digital identity schemes and are deployed in close to 120 out of 145 countries implementing e-government programs. Used in many sovereign electronic documents such as ePassports, citizen cards, national ID cards, driving licenses, social security cards and, health cards, SmartMX-based services protect citizens from identity theft and reduce fraud via the products’ world class security features. The SmartMX family is also the preferred technology for the secure element of NFC-enabled phones.

About MTCOS
MTCOS Protects identities in more than 65 countries. MTCOS has been designed for smart card and embedded security ICs with crypto-coprocessor and contactless-, contact based- or dual interface. MTCOS is a true multiapplication OS with advanced public key support. It is compliant to all relevant open ISO/IEC standards for smart cards and contains a unique range of eID applications already built-in the OS. MTCOS is certified Common Criteria EAL4+/5+ on different high secure semiconductor types.

About NXP
NXP Semiconductors N.V. (NASDAQ:NXPI) enables secure connections and infrastructure for a smarter world, advancing solutions that make lives easier, better and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the secure connected vehicle, end-to-end security & privacy and smart connected solutions markets. Built on more than 60 years of combined experience and expertise, the company has 44,000 employees in more than 35 countries and posted revenue of $6.1 billion in 2015. Find out more at www.nxp.com.

About MaskTech
MaskTech is the leading independent manufacturer and supplier of high security smart card operating systems (MTCOS) for government and industry use. MaskTech’s portfolio includes generic and customized mask solutions for state-of-the-art Common Criteria certified smart card and contactless cryptographic chipsets. The company supplies more than 30 major passport manufacturers and system integrators and holds a leading position in all of its primary product categories. Find out more at www.masktech.com.         

For more information, please contact:

Americas
Tate Tran	
Tel: +1 408-802-0602
Email:tate.tran@nxp.com

Europe 
Martijn van der Linden
Tel: +31 6 10914896
Email: martijn.van.der.linden@nxp.com

Greater China / Asia 
Esther Chang
Tel: +886 2 8170 9990
Email: esther.chang@nxp.com
Thursday, September 29th, 2016 Uncategorized Comments Off on $NXPI Delivers Enhanced Anti-Cloning Security Solution

$CATB & $SRPT Joint Research #Collaboration in #MuscularDystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company (“Catabasis”), and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics (“Sarepta”), today announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD). The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.

“We are excited to work with Sarepta on this joint research collaboration, which to our knowledge is the first time two companies are testing a combination of investigational therapies to treat Duchenne. Although we believe edasalonexent (CAT-1004) has the potential to be a disease-modifying monotherapy, we think there is benefit to exploring innovative ways to make the most meaningful difference in this devastating disease”, said Jill C. Milne, Ph.D., chief executive officer of Catabasis. “In addition to our continued development of edasalonexent, we are pleased to take the first step via this collaboration to determine if edasalonexent may be complementary to an exon-skipping treatment strategy in the treatment of DMD using a preclinical model.”

“We recognize the extreme unmet medical need in DMD and are committed to determining the best treatment strategies for patients affected by Duchenne,” said Edward Kaye, M.D., Sarepta’s chief executive officer. “We believe exon skipping has the potential to target the underlying genetic cause of the disease by restoring the mRNA reading frame to produce dystrophin in skeletal muscle. We are pleased to initiate activities with Catabasis to evaluate a potential combination treatment approach of exon-skipping and NF-kB inhibition in DMD.”

NF-kB inhibition and exon-skipping represent two novel investigational treatment strategies in Duchenne, each with the potential for disease-modifying effects when used as monotherapy. The objective of the joint research is to study the safety and efficacy of combining these two treatment strategies using a mouse model of DMD, including evaluating the potential for additional or synergistic benefits.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company’s drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an oral small molecule that has the potential to be a disease-modifying therapy for all patients affected by Duchenne muscular dystrophy (DMD or Duchenne), regardless of the underlying mutation. Edasalonexent inhibits NF-kB, a protein that is activated in Duchenne and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. In animal models of DMD, edasalonexent inhibited NF-kB, reduced muscle degeneration and improved muscle regeneration and function, and beneficial effects were observed in skeletal, diaphragm and cardiac muscle. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. We have previously reported safety, tolerability and reduction in NF-kB activity in Phase 1 trials in adults. We are currently conducting the MoveDMD® trial of edasalonexent in 4-7 year-old boys affected by Duchenne. From Part A of the MoveDMD trial, we have reported that edasalonexent was generally well tolerated with no safety signals observed and we observed successful NF-kB target engagement. Pharmacokinetic results demonstrated edasalonexent plasma exposure levels consistent with those previously observed in adults at which inhibition of NF-kB was observed.

About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway. For more information, please visit us at www.sarepta.com.

About Duchenne Muscular Dystrophy
DMD is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500-5,000 males worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and death usually occurs before the age of 30.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Catabasis and/or Sarepta, including statements about future clinical trial plans and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the joint research collaboration plans of Sarepta and Catabasis to explore a combination drug treatment approach for DMD and the potential benefit of the products being researched in DMD. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Catabasis’ or Sarepta’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for Catabasis’ or Sarepta’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of Catabasis’ or Sarepta’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of each of Catabasis’ and Sarepta’s Quarterly Report on Form 10-Q for the period ended June 30, 2016, which are each on file with the Securities and Exchange Commission, and in other filings that Catabasis or Sarepta may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent Catabasis’ and Sarepta’s views as of the date of this press release. Each of Catabasis and Sarepta anticipates that subsequent events and developments will cause their respective views to change. However, while either Catabasis or Sarepta may elect to update these forward-looking statements at some point in the future, each company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the views of either Catabasis or Sarepta as of any date subsequent to the date of this release.

 

Catabasis Investor and Media Contact:
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
or
Sarepta Therapeutics, Inc.
Media and Investors:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com

Thursday, September 29th, 2016 Uncategorized Comments Off on $CATB & $SRPT Joint Research #Collaboration in #MuscularDystrophy

$BIOC #TargetSelector Platform Performance to be Presented at the 2016 #ESMO

SAN DIEGO, Sept. 29, 2016  — Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that clinical results featuring its liquid biopsy platform will be presented at the 2016 European Society For Medical Oncology (ESMO) Annual Congress, taking place October 7-11 in Copenhagen, Denmark. Study results highlighting the concordance and clinical utility of detecting actionable biomarkers in patients with advanced non-small cell lung cancer (NSCLC) will be presented by Lourdes Barrera, Ph.D., Diagnostics Manager, AstraZeneca Oncology BU, Mexico. An abstract for the presentation can be found at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/546#2z95w

Presentation Details:

Title: Clinical evaluation of the utility of a liquid biopsy (circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients
Date and Time: Sunday, October 9, 2016, 4:30 p.m. CEST (Central European Summer Time) Basic Science and Translational Research; Poster Discussion Session: Berlin Room, Central Hall

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit www.biocept.com.

Physicians interested in ordering Biocept’s liquid biopsy tests for cancer biomarkers should contact Customer Service at 858-320-8206, or visit http://biocept.com/medical-professionals/.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Thursday, September 29th, 2016 Uncategorized Comments Off on $BIOC #TargetSelector Platform Performance to be Presented at the 2016 #ESMO

$APTI Announces Closing Of #IPO

BELLEVUE, Wash., Sept. 28, 2016  — Apptio, Inc. (NASDAQ: APTI), the leading provider of cloud-based Technology Business Management, or TBM, software, today announced the closing of its initial public offering of 6,900,000 shares of Class A common stock at a price to the public of $16.00 per share, which includes the full exercise of the underwriters’ option to purchase 900,000 additional shares. The company estimates net proceeds from the offering to be approximately $99.4 million, after deducting underwriting discounts and commissions and estimated offering expenses. The shares began trading on the NASDAQ Global Market under the ticker symbol “APTI” on September 23, 2016.

Goldman, Sachs & Co., J.P. Morgan Securities LLC and BofA Merrill Lynch acted as joint lead bookrunners for the offering, while Barclays Capital Inc., Jefferies LLC, RBC Capital Markets, LLC and Pacific Crest Securities, a division of KeyBanc Capital Markets Inc., acted as bookrunners.

The offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus related to the offering may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by e-mail at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC  28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 22, 2016. Copies of the registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Wednesday, September 28th, 2016 Uncategorized Comments Off on $APTI Announces Closing Of #IPO

$EFOI Launches Network-Ready Lighting Solutions

Innovative retrofit 100-percent flicker-free TLED lighting options create opportunity for vast energy savings

SOLON, Ohio, Sept. 28, 2016  — Energy Focus, Inc. (NASDAQ:EFOI), a leader in LED lighting technologies, today announced the launch of two new products, 500NR Network-Ready Series LED Tube and Intellitube® NR Network-Ready Tube.

Created with high-quality components, these are the first retrofit TLEDs on the market to put dimming technology directly inside the tubes. This Internet of Things technology enables the UL-approved tubes to be directly connected to and controlled by the building’s automation system or lighting control system. In addition to the 50-percent energy savings of switching to LED, building owners can save approximately 20-percent more by utilizing the dimming feature.

“At Energy Focus we are devoted to engineering products that make our customers’ lives easier and more efficient,” said Jeremy Heilman, Vice President of Research and Development. “Our network-ready, 100-percent flicker-free tubes ensure our customers are using the least amount of power to produce a bright amount of healthy light, and result in over 50-percent energy savings.”

The Intellitube® NR Network-Ready Tube adds Network Readiness to the Intellitube’s® innovative features, making it easier than ever for companies to meet their lighting needs with controllable LED solutions. Launched in 2015, the Intellitube® is Energy Focus’s commercial adaptation of the LED lighting solution the company developed in cooperation with DARPA for use in combat-ready Navy ships. The Intellitube’s® patented dual-mode design makes retrofit of old fluorescent light fittings with new LED lighting tubes easy and safe. The Intellitube® is compatible with a wide variety of fluorescent ballasts, a necessary component needed to regulate the current to fluorescent lighting. Intellitubes® can also work without a ballast, utilizing its integrated, auto-ranging universal line LED driver.

The 500NR Network-Ready Series LED Tube is an upgrade on Energy Focus’s 500D direct wire solution, which operates without a ballast. The 500NR is engineered so that all the circuitry needed to operate the tube is located inside the tube, eliminating the need for the costly and inefficient external drivers and other components. Eliminating the ballast allows a building owner to save five to ten additional watts per fixture, which contributes to incremental savings.

Both the Intellitube® NR Network-Ready Tube and the 500NR Network-Ready Series LED Tube come in various lengths ranging from 2’/24” to 4’/48”, several color temperature and maximum brightness options, and integrated LED drivers. Performance is maintained across the board, with 150lm/W for all powers, all colors, in the clear lens, and 140lm/W with the frosted diffusing lens, reducing the power required to provide equivalent light levels of a 4-foot fluorescent tube from 28-32 watts to merely 11 watts.

These solutions continue Energy Focus’s commitment to high-performance, low-cost retrofit and both provide a pathway to eliminate ballasts from the lighting system, either at the time of installation or during normal maintenance. Building owners are saving the risk and cost of replacing an exterior ballast and the additional energy and cost savings that come from eliminating the inefficiency of a ballast.

To learn more about the UL-approved 500NR Network Ready Series LED Tube and the Intellitube® Network Ready Tube, please call 1-800-327-7877 or visit energyfocus.com.

About Energy Focus, Inc. 

Energy Focus, Inc. is a leading provider and innovator of energy efficient LED lighting products. As the creator of the only 100-percent flicker-free LED products on the market, Energy Focus products provide extensive energy savings, aesthetics, safety and health benefits over conventional and fluorescent lighting. As a long standing partner with the US Government providing energy efficient LED lighting products to the U.S. Navy and the Military Sealift Command fleets, Energy Focus products go through rigorous testing in the most adverse conditions possible and still have a zero percent failure rate. In the commercial sphere, customers include national, state and local U.S. government agencies as well as Fortune 500 companies across education, healthcare, retail and manufacturing. Energy Focus is headquartered in Solon, Ohio, with additional sales offices in Washington, D.C., New York and Taiwan.

Media and Investor Contacts:

Michael Miller
Content Strategist, Energy Focus, Inc.
msmiller@energyfocusinc.com
(440) 715-1300 Office or (734) 945-6359 Cell
Or
Peter Seltzberg, Darrow Associates, Inc.
pseltzberg@darrowir.com
516-419-9915
Wednesday, September 28th, 2016 Uncategorized Comments Off on $EFOI Launches Network-Ready Lighting Solutions

$AEGR #JUXTAPID Capsules Approved in #Japan for #HoFH

CAMBRIDGE, Mass., Sept. 28, 2016  — Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan’s Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).

HoFH is a serious, rare genetic disease that impairs the function of the receptor responsible for removing LDL-C (“bad” cholesterol) from the body. A loss of LDL receptor function results in extreme evaluation of blood cholesterol levels. HoFH patients often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.

Chief Executive Officer of Aegerion Mary Szela said, “This approval marks a significant milestone in our ongoing efforts to maximize the value of JUXTAPID. Japan is an important market and since lomitapide was granted orphan drug designation for HoFH in 2013, we have worked to establish disease awareness among the HoFH community. We look forward to the opportunity to provide an additional therapeutic option for patients with this severe rare disease. Our team is focused on the upcoming commercial launch, assuming reimbursement approval, and working with Japanese healthcare providers to identify and serve those patients appropriate for JUXTAPID therapy.”

The MHLW based its approval of JUXTAPID on Aegerion’s Phase III study in Japanese patients, which evaluated the safety and efficacy of the medicine to reduce LDL-C levels in nine patients with HoFH. The findings were consistent with the known safety and efficacy profile of JUXTAPID.

JUXTAPID is approved in the United States as an adjunct to a low-fat diet and other lipid lowering treatments, including apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with HoFH.  In the U.S., JUXTAPID carries a boxed warning for the risk of hepatotoxicity. The boxed warning also states that JUXTAPID should only be prescribed to patients with a clinical or laboratory diagnosis consistent with HoFH, and that the safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH. Because of the risk of hepatotoxicity and the importance of JUXTAPID only being prescribed to patients with a clinical or laboratory diagnosis consistent with HoFH, JUXTAPID is only available through the JUXTAPID REMS Program.  The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

Important Safety Information from U.S. Prescribing Information, including BOXED WARNING which states:

WARNING: RISK OF HEPATOTOXICITY

JUXTAPID can cause elevations in transaminases. In the JUXTAPID clinical trial, 10 (34%) of the 29 patients treated with JUXTAPID had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase.

JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% at baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of JUXTAPID if the ALT or AST are ≥3x ULN. Discontinue JUXTAPID for clinically significant liver toxicity.

Because of the risk of hepatotoxicity, JUXTAPID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the JUXTAPID REMS PROGRAM.

CONTRAINDICATIONS

  • Pregnancy
  • Concomitant administration of moderate or strong CYP3A4 inhibitors
  • Moderate or severe hepatic impairment or active liver disease including unexplained persistent elevations of serum transaminases

WARNINGS AND PRECAUTIONS

JUXTAPID can cause elevations in transaminases and hepatic steatosis. Although cases of hepatic failure have not been reported, there is concern that JUXTAPID could induce steatohepatitis, which can progress to cirrhosis over several years. Modify the dose of JUXTAPID if elevations of transaminases are observed and discontinue JUXTAPID for persistent or clinically significant elevations. If transaminase elevations are accompanied by clinical symptoms of liver injury, such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like-symptoms, increases in bilirubin ≥2x ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause. Use JUXTAPID with caution when co-administered with agents known to be hepatotoxic. Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury.

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment. During the first year, measure liver-related tests (ALT and AST, at a minimum) prior to each increase in dose or monthly, whichever occurs first. After the first year, do these tests at least every three months and before any increase in dose.

Females of reproductive potential should have a negative pregnancy test before starting Juxtapid and should use effective contraception during therapy with Juxtapid. The recommended maximum dosage of Juxtapid is 40 mg daily when used concomitantly with oral contraceptives.

Given its mechanism of action in the small intestine, JUXTAPID may reduce the absorption of fat-soluble nutrients. Patients treated with JUXTAPID should take daily supplements that contain 400 international units vitamin E and at least 200 mg linoleic acid, 210 mg alpha-linolenic acid (ALA), 110 mg eicosapentaenoic acid (EPA), and 80 mg docosahexaenoic acid (DHA).

Gastrointestinal adverse reactions are common and may lead to treatment discontinuation. To reduce the risk of gastrointestinal adverse reactions, patients should adhere to a low-fat diet supplying less than 20% of energy from fat and the dosage of JUXTAPID should be increased gradually.

Weak CYP3A4 inhibitors can increase the exposure of lomitapide approximately two-fold; therefore, when JUXTAPID is administered with weak CYP3A4 inhibitors, the dose of JUXTAPID should be decreased by half and the recommended maximum dosage of JUXTAPID is 30 mg daily. The recommended maximum dosage is 40 mg daily when used concomitantly with oral contraceptives. Strong and moderate CYP3A4 inhibitors should not be used with Juxtapid.  Patients taking JUXTAPID 5 mg daily may continue with the same dosage.
Due to risk of myopathy associated with simvastatin or lovastatin, doses of these agents should be limited when co-administered with JUXTAPID.

JUXTAPID increases the plasma concentrations of warfarin. Increases or decreases in the dose of JUXTAPID may lead to supra- or subtherapeutic anticoagulation, respectively. Patients taking warfarin should undergo regular monitoring of the INR, especially after any changes in JUXTAPID dosage.

Avoid use of JUXTAPID in patients with rare hereditary disorders of galactose intolerance.

About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  For more information about the company, please visit www.aegerion.com.

Forward Looking Statements:

This press release contains forward-looking statements, including statements regarding the potential for launch and commercialization of JUXTAPID in Japan. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other factors; the risk that we may not be able to obtain pricing and reimbursement approval in Japan at acceptable levels or at all; the risk that JUXTAPID may not gain market acceptance in Japan; and the other risks inherent in the commercialization process. For additional disclosure regarding these and other risks we face, see the disclosure contained in the “Risk Factors” section of Aegerion’s Quarterly Report on Form 10-Q filed on August 9, 2016, and our other public filings with the Securities and Exchange Commission, available on the SEC’s website at http://www.sec.gov. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Investors and others should note that we communicate with our investors and the public using our company website (www.aegerion.com) and our investor relations website (http://ir.aegerion.com), including but not limited to company disclosures; investor presentations and FAQs; Securities and Exchange Commission filings; press releases; public conference calls and webcasts. The information that we post on these websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

CONTACT:
Aegerion Pharmaceuticals, Inc.                                                        
Amanda Murphy, Associate Director, Investor & Public Relations                                 
857-242-5024  
Amanda.murphy@aegerion.com
Wednesday, September 28th, 2016 Uncategorized Comments Off on $AEGR #JUXTAPID Capsules Approved in #Japan for #HoFH

$AVXL Compound to be Tested in $BIIB #Neuroprotectant Model

NEW YORK, Sept. 28, 2016  — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that it has signed a material transfer agreement with Biogen (Cambridge, MA) under which Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A satisfactory result from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model.

“Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail.  Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.

About Biogen

Through cutting-edge science and medicine, Biogen (Nasdaq:BIIB) discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

 

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:  info@anavex.com

Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com

Media:
Dennis Dobson, Jr.
Dobson Media Group
(203) 258-0159
dennisdobsonjr@dobsonmediagroup.com
Wednesday, September 28th, 2016 Uncategorized Comments Off on $AVXL Compound to be Tested in $BIIB #Neuroprotectant Model

$IPDN Discusses Impact of #ReverseStockSplit on #SelfTender Offer

CHICAGO, Sept. 28, 2016  — Professional Diversity Network, Inc. (“PDN” or “the Company”) (NASDAQ:IPDN), a developer and operator of online networks that provide networking and access to employment opportunities for women and other diverse professionals in the United States, today provided an overview of its recent reverse stock split and its partial self-tender offer.

HIGHLIGHTS:

  • As previously announced, at the Annual Meeting of Stockholders held on September 26, 2016, the Company’s stockholders approved the proposal authorizing the Board of Directors to implement the reverse stock split at a ratio within the range from 1-for-2 to 1-for-15, and to amend the Company’s Amended and Restated Certificate of Incorporation to effect the reverse stock split and to proportionately reduce the number of shares of common stock the Company is authorized to issue.
  • The Board of Directors approved a final 1-for-8 ratio immediately following the Annual Meeting of Stockholders.
  • The reverse stock split was effective as of 12:01 a.m. EDT on September 27, 2016.  The Company’s shares continue to trade, on a post-split basis, under ticker symbol IPDN on the NASDAQ Capital Market.
  • The reverse stock split reduced the Company’s outstanding shares from approximately 14.5 million to approximately 1.8 million, and its authorized shares from 25 million to approximately 3.1 million.
  • The reverse stock split proportionally affects the number of shares expected to be issued at the closing of the Company’s previously-announced transaction with Cosmic Forward Limited (“CFL”), as well as the number of shares the Company is seeking to purchase in its previously-announced partial self-tender offer and the per-share transaction prices.
  • The CFL transaction would still result in the purchase by CFL of 51% of the Company’s outstanding shares, on a fully-diluted basis, but the purchase of the shares will be at $9.60 per share rather than the previously-announced $1.20 share (which reflected an approximately 126% premium over the closing price of the common stock on August 12, 2016, the day on which the CFL transaction was announced).
  • The partial self-tender offer will now be for up to 312,500 shares of the Company’s common stock at a price of $9.60 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and conditions set forth in the offer to purchase dated September 28, 2016.

About Professional Diversity Network, Inc.

The Professional Diversity Network platform provides employers that value diversity with access to diverse talent to meet their hiring needs. Professional Diversity Network owns and operates professional networking communities including: www.iHispano.com for Hispanic professionals, www.BlackCareerNetwork.com for African-American professionals, www.WomensCareerChannel.com for professional women, www.Military2Career.com for Veterans, http://www.ProAble.net for professionals with disabilities, www.OutProNet.com for professionals in the LGBT community, and www.AsianCareerNetwork.com for Asian-American professionals.  In addition, the Company operates the National Association of Professional Women, at www.napw.com, the country’s largest networking organization dedicated to professional women.  For more information, visit: www.prodivnet.com.

Forward Looking Statements: This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions.  Forward-looking statements can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or similar words, and include, without limitation, statements regarding the shares to be issued to CFL. Forward-looking statements involve risks and uncertainties and our actual results may differ materially from those stated or implied in such forward-looking statements. Factors that could contribute to such differences include, but are not limited to: the ability to meet the closing conditions to the completion of the sale of shares to CFL; potential failure by the Company to increase its total market capitalization following the reverse stock split, failure to maintain the increased per-share stock price over the long term, failure to generate investor interest, potential adverse effect of the reduced number of shares outstanding following the reverse stock split on the liquidity of the Company’s common stock; and the risk factors disclosed in our Annual Report on Form 10-K filed on March 30, 2016, Quarterly Report on Form 10-Q filed on August 15, 2016 and any subsequent filings made by us with the SEC.  We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K filed on March 30, 2016 and the Form 10-Q filed on August 15, 2016 together with this press release, are available on our website, www.prodivnet.com. Please click on “Investor Relations.”

Additional Information and Where to Find It

This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of PDN or a solicitation of any vote or approval. In connection with the proposed CFL transaction, PDN has filed with the SEC and mailed to stockholders a proxy statement on Schedule 14A.  Stockholders are urged to read the proxy statement and other relevant materials (including any amendments or supplements thereto) because they contain important information.

The tender offer is being made only through the offer to purchase and related materials, which PDN will file with the SEC. Stockholders are urged to read these materials when they become available because they will contain important information.

The proxy statement and other relevant materials and the offer to purchase and related tender offer materials, and any other documents filed by PDN with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, security holders may obtain free copies of the proxy statement and tender offer materials  from PDN by contacting Christopher Wesser by telephone at 516-659-8560, or by mail to Professional Diversity Network, Inc., Attention: Secretary, 801 W. Adams Street, Suite 600, Chicago, Illinois 60607 or by going to the “Investor Relations” page of PDN’s corporate website at www.prodivnet.com.  Tender offer materials can also be obtained free of charge from Continental Stock Transfer & Trust, the Depositary for the tender offer, by telephone at (917) 262-2378, or by mail to Continental Stock Transfer & Trust Company, Inc., 17 Battery Place, 8th Floor, New York, NY 10004.

PDN
Christopher Wesser, EVP & Secretary
(516) 659-8560
investor@prodivnet.com
Wednesday, September 28th, 2016 Uncategorized Comments Off on $IPDN Discusses Impact of #ReverseStockSplit on #SelfTender Offer

$XXII Overwhelming Physician & Consumer Support for #X22 Quit #Smoking Aid

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced results from two separate independent surveys showing that strong consumer demand mirrors physicians’ willingness to prescribe the Company’s X-22 smoking cessation aid in development.

X-22 is a Very Low Nicotine tobacco-based botanical medical product for smoking cessation. Independent clinical studies have demonstrated that combustible cigarettes containing 22nd Century’s Very Low Nicotine tobacco with non-addictive levels of nicotine enable smokers to disassociate the act of smoking from the rapid intake of nicotine. X-22 involves the same smoking behavior as conventional cigarettes and does not expose the smoker to any new drugs or new side effects. 22nd Century has an active Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) relating to the X-22 smoking cessation product.

To assess consumer reaction to X-22, the first survey, conducted by Survata, an independent market research firm based in San Francisco, California, questioned 501 current smokers in the United States, who have tried to quit at least once, about their failed quit attempts. Participants were then given a brief overview of 22nd Century’s X-22 Very Low Nicotine cigarettes designed for use as a prescription smoking cessation aid. Overall, the vast majority of smokers expressed strong enthusiasm for 22nd Century’s X-22 product to become available at U.S. pharmacies. Indeed, of the 501 smokers surveyed, if X-22 were currently available:

  • 89% said X-22 would be their top or first choice to help them quit smoking.
  • 88% indicated that they would have attempted to quit smoking sooner if X-22 had been available when they first considered quitting.
  • 85% would pursue a prescription for X-22 from their doctor to help them quit smoking.

22nd Century also commissioned surveys (conducted by Survata and by Dobrin Consulting in Richmond, Virginia) of 136 practicing physicians who have experience in helping patients quit smoking. Physicians reviewed detailed information regarding the use and efficacy of X-22, including published results from several of the numerous independent clinical trials that have been conducted with cigarettes made with 22nd Century’s proprietary Very Low Nicotine tobacco. Most importantly, of the 136 physicians surveyed:

  • 89% said that they would prescribe X-22 cigarettes to help their patients quit smoking.
  • 75% selected the descriptive phrase: “addresses the behavioral aspects of smoking” as the most appealing aspect of X-22.
  • 70% listed “reduces cravings” as a highly appealing feature of X-22.
  • More than 50% mentioned “no new side effects” among the most compelling reasons to recommend X-22 to their patients.

“When you have hard data asserting that 89% of physicians will prescribe your product – paired with rapidly growing support in the scientific community – I think we conclusively put to rest any questions about the potential for X-22 as a blockbuster smoking cessation drug,” explained James Vail, Director of Business Development at 22nd Century Group.

Mr. Vail will share more detailed consumer and physician survey results October 5-7 at BioNetwork’s Partnering Summit in Laguna Niguel, California. BioNetwork’s annual event brings together the decision-makers and business development executives from the pharmaceutical and biotechnology industries to initiate strategic partnerships. Mr. Vail will also share an overview of the now 15 completed and 19 on-going independent clinical research studies using the Company’s Very Low Nicotine tobacco. Since 2015, the number of published studies using 22nd Century’s proprietary Very Low Nicotine tobacco has more than doubled. The results of these studies have been overwhelmingly favorable. Of notable importance, an independent clinical study, funded in part by the FDA, and published in the October 2015 issue of The New England Journal of Medicine, found that smokers of 22nd Century’s VLN cigarettes consumed far fewer cigarettes per day and doubled their quit attempts versus smokers of conventional cigarettes.

“Given the opportunity, a vast majority of informed physicians report that they will prescribe X-22 to patients who wish to quit,” explained Henry Sicignano, III, President and CEO of 22nd Century Group. “Considering this enthusiasm, in conjunction with the fact that nearly 90% of surveyed smokers indicate that they are eager to try X-22, we have all of the ingredients for a tremendous commercial success… indeed, a success that will save millions of lives and billions of dollars in healthcare costs.”

Phase II and Phase III clinical results collected by scientific researchers around the world have demonstrated the safety and efficacy of 22nd Century’s proprietary Very Low Nicotine tobacco cigarettes. Independent clinical trials utilizing 22nd Century’s Very Low Nicotine cigarettes to treat more than 4,000 total smokers have shown increased quit rates, whether the Very Low Nicotine cigarettes were used alone; used concurrently with nicotine replacement therapies, such as nicotine gums, nicotine patches, and nicotine lozenges; or used concurrently with Pfizer’s Chantix®. A summary of 34 independent clinical research studies and 10 scientific opinion pieces related to 22nd Century’s Very Low Nicotine tobacco are available on the Company’s Heracles Pharmaceuticals’ website at: http://heraclespharma.com/clinical-trials-2/

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. Visit www.xxiicentury.com and www.heraclespharma.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed on February 18, 2016, including the section entitled “Risk Factors,” and our other reports filed with the U.S Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

Investor Relations:
IRTH Communications
Andrew Haag, 866-976-4784
xxii@irthcommunications.com
or
Redington, Inc.
Tom Redington, 203-222-7399

Tuesday, September 27th, 2016 Uncategorized Comments Off on $XXII Overwhelming Physician & Consumer Support for #X22 Quit #Smoking Aid

$OASM Annual General Meeting 2016 Communique

Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held its Annual General Meeting for the fiscal year 2015/2016 on Monday, September 26, 2016, where and the following main resolutions were made. For detailed information about the content of the resolutions, see the complete notice for Annual General Meeting which is available on Oasmia’s website www.oasmia.com, together with the complete proposals for the resolutions below.

Uppsala, Sweden, Sept. 27, 2016  — Establishment of Balance Sheet and Income Statement
The Annual General Meeting established the Balance Sheet, Income Statement, Consolidated Accounts and Financial report. It was resolved that the share premium reserve of SEK 941 960 675, accumulated result of SEK -489 921 393 and result for the year SEK -141 673 259, in total SEK 310 366 023, shall be carried forward.

The Board of Directors and auditors
The Annual General Meeting discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2015/2016. The resolution also included the Members of the Board who resigned during the year. The Annual General Meeting made a resolution that the Board shall consist of six regular members without deputies. The Annual General Meeting re-elected the Board members Julian Aleksov, Bo Cederstrand, Horst Domdey, Alexander Kotsinas, Hans Sundin and Lars Bergkvist. Julian Aleksov was elected as Executive Chairman of the Board. Ernst & Young AB, with principal auditor Fredrik Norman, was elected as auditors.

Remuneration to the Board and auditors
The Annual General Meeting established that a member of the Board, not employed by the company, shall receive remuneration amounting to SEK 150,000. The Chairman of the Board shall receive payment of SEK 175,000. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly-owned by the Board member. In that case, the invoiced fee will be increased by the amount of social security contributions and VAT. Remuneration to the auditors shall be paid according to bill.

Guidelines for remuneration to senior managers
The Annual General Meeting approved the guidelines for remuneration to senior managers proposed by the Board.

Nomination committee
The Annual General Meeting approved the proposal concerning criteria for the selection of a nomination committee for the Annual General Meeting 2017.

The Board’s proposal for the authorization of repurchase and transfer the company’s own shares
The Annual General Meeting made a resolution to authorize the Board of Directors to resolve to repurchase, on one or several occasions prior to the next Annual General Meeting, as many shares as may be purchased without the company’s holding at any time exceeds 10 per cent of the total number of shares in the company. The shares shall be purchased on NASDAQ Stockholm and only at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.

The Board of Directors was also authorized to resolve, on one or several occasions during the period until the next annual general meeting, to transfer all shares held by the company, via NASDAQ Stockholm or in connection with the acquisition of companies, businesses or parts thereof on market terms, however, not to a price lower than the current stock market value. Transfer of shares on the NASDAQ Stockholm may be made at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.

Authorization for the Board to propose new issue of share, warrants and convertibles
The Annual General Meeting made a resolution, in accordance with the proposal by the Board, to authorize The Board to, on one or several occasions for the period up to the next Annual General Meeting, resolve on an issue of shares, warrants and/or convertible instruments with or without deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act. The board of directors shall however not be entitled to make resolutions which entail that the share capital is increased with more than SEK 3,500,000.

The new shares, warrants and/or convertible instruments shall, in the event of a deviation from the shareholders’ pre-emption rights, be issued at a subscription price which connects to the stock price at the time of the issue, decreased by a market rate discount that the board of directors deems necessary (if any).

Other information
For the sake of clarity, no other new information, not previously communicated to the market, was released at the meeting.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Mikael Asp, CEO
Tel: +46 18 50 54 40
E-mail: mikael.asp@oasmia.com

Tuesday, September 27th, 2016 Uncategorized Comments Off on $OASM Annual General Meeting 2016 Communique

$INVT, #Pabellon #ProofOfConcept via Fortune 100 Company Engagement

First Commercial Engagement by One of the Partners of the Inventergy Innovations Subsidiary

CAMPBELL, CA–(Sep 27, 2016) – Inventergy Global, Inc. (NASDAQ: INVT), (“Inventergy”) an intellectual property licensing company, announced today that Pabellon, Inc. (“Pabellon”), one of the new partners of Inventergy Innovations, LLC, Inventergy’s recently launched subsidiary, is currently engaged with a Fortune 100 company to create a proof of concept (POC) to demonstrate its breakthrough Surface Plane Magnetic Technology™ to continuously charge remote internet devices. The power, sent via Pabellon’s surface plane magnetics will be extracted by miniaturized, patented Pabellon receivers mounted on sensory devices. Power is delivered to remote sensing devices and return path data is extracted from these devices to create “smart” sensing environments for many applications.

As part of the engagement, Pabellon plans to demonstrate power, data and sensory applications, which are enabled using Pabellon’s surface plane magnetic technology. Importantly, data can be transmitted via secure modulation techniques using Pabellon’s technology. Miniaturized receivers can also sense disturbances for security applications.

Joe Beyers, CEO of Inventergy, stated, “Launching this POC demonstrates the significant value opportunity we create for our partners through a unique monetization model that can quickly provide commercialization opportunities on a much larger scale. In less than 10 weeks after forming a partnership with Inventergy Innovations, Pabellon is now heavily engaged with a large multi-national company. We will continue to seek opportunities with targeted investment, shorter time for execution, lower up-front capital outlays and lower operating costs, generating higher returns that can expand our revenue opportunities for our stakeholders.”

“We believe that Pabellon’s technology can remove barriers impairing the conventional wireless power transfer industry, enabling last mile complete solutions. Pabellon’s patented technology opens up unprecedented connectivity for non-radiative power, data and sensing applications,” stated Ken Cannizzaro, President of Inventergy Innovations. “The market opportunity for this technology is growing rapidly in a number of potential multi-billion dollar market segments.”

“We are confident that this POC will have a positive outcome and demonstrate the value of our innovative technology,” said Alex Rubin, CEO and Founder of Pabellon, Inc. “We are also delighted with our engagement with Inventergy. They have helped us to enrich and enhance our IP protection, and refine and focus our value proposition, leading up to this exciting new engagement.”

About Inventergy Global, Inc.
Inventergy Global, Inc. is a Silicon Valley-based intellectual property company dedicated to identifying, acquiring and licensing patented technologies of market-significant technology leaders. Led by IP industry pioneer and veteran Joe Beyers, the Company leverages decades of corporate experience, market and technology expertise, and industry connections to assist Fortune 500 and other technology companies in leveraging the value of their innovations to achieve greater returns. For more information about Inventergy, visit www.inventergy.com.

About Pabellon, Inc.
Pabellon’s technology enables connector-less, wireless power /data transfer and remote sensing applications for mobile, IoT (Internet of Things) and lighting applications. Pabellon’s Surface Plane Magnetic Technology™ sends an oscillating magnetic field along the surface of objects such as desks, walls, pipes and fabrics to miniaturized receiver devices that can extract power and data. Disturbances in the field are detectable by the receiver devices, enabling sensory applications such as human presence detection and touch-free controls.

Pabellon’s technology is aimed at the markets for wearables, intrusion detection, as well as toys and lighting which each offers multiple billion dollar addressable markets. According to research firm MarketsandMarkets, the wearable technology market is expected to reach $31.3 billion by 2020, at a CAGR of 17.8% between 2015 and 2020. MarketsandMarkets reported that the global intrusion detection system/intrusion prevention (IDS/IPS) security market was estimated at $2.7 billion in 2014 and is expected to grow to $5.0 billion in 2019.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements, estimates, forecasts and projections with respect to future performance and events, which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent and belief or current expectations of the Company and its affiliates and subsidiaries and their respective management teams. These statements may be identified by the use of words like “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “should,” “seek” and similar expressions and include any projections or estimates set forth herein. Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, that actual results may differ materially from those projected in the forward-looking statements.

Tuesday, September 27th, 2016 Uncategorized Comments Off on $INVT, #Pabellon #ProofOfConcept via Fortune 100 Company Engagement

$KTOV Successful Results #KIT302 Pharmacokinetic Bioequivalence Study

KIT-302 Successfully Meets U.S. Food and Drug Administration Bioequivalence Standards for 2.5 mg Amlodipine Dose

TEL AVIV, Israel, September 27, 2016  —

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, announced today that its lead drug candidate KIT-302 has successfully completed an additional pharmacokinetic (PK) bioequivalence (BE) study and once more successfully met the U.S. Food and Drug Administration’s (FDA) standards for establishing bioequivalence to the reference drugs. The current study evaluated a lower dosage (2.5 mg) of amlodipine than in Kitov’s previous PK bioequivalence study for the KIT-302 product containing 10 mg of amlodipine, the results of which were announced by Kitov on May 10, 2016.

“We are pleased with the results of our additional pharmacokinetic BE study, which brings us closer towards submitting our New Drug Application to the FDA for KIT-302 as planned,” stated Dr. J. Paul Waymack, Chairman of Kitov’s Board and Chief Medical Officer.

The study compared the PK of Kitov’s combination drug KIT-302 in a fixed dose combination consisting of 200 mg of celecoxib, indicated for osteoarthritis pain, and 2.5 mg of amlodipine, indicated for high blood pressure, to off-the-shelf branded 200 mg celecoxib capsules and 2.5 mg amlodipine tablets. These evaluations were conducted under both fed and fasted conditions. The results demonstrated that for both the Cmax (the maximum blood level achieved) and Area Under the Curve (the area under the concentration time curve for drug levels), the 90% confidence intervals for both the amlodipine and celecoxib components of KIT-302 were documented to be between 80% and 125% of the values obtained with the off-the-shelf drugs.  With these study results, Kitov has again met the FDA standard for demonstrating BE under both fed and fasted conditions.

About KIT-302

KIT-302 is intended to treat pain caused by osteoarthritis (OA), as well as simultaneously treat hypertension, which is a common side effect of certain stand-alone drugs that treat osteoarthritis pain, as well as a common concomitant preexisting condition. KIT-302 is comprised of two U.S. Food and Drug Administration (FDA) approved drugs, celecoxib (the active ingredient in Pfizer’s Celebrex®), for the treatment of pain caused by osteoarthritis and amlodipine besylate (the active ingredient in Pfizer’s Norvasc®), a drug designed to treat hypertension. Kitov expects to submit a New Drug Application for KIT-302, which successfully completed a pivotal Phase III trial, with the U.S. Food and Drug Administration within the coming months.

Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.).  Norvasc® is a registered trademark of Pfizer Inc.

About Kitov Pharmaceuticals

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s pipeline currently features two combination drugs intended to treat osteoarthritis pain and hypertension simultaneously, including one that achieved the primary efficacy endpoint for its Phase III clinical trial. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.

Forward-Looking Statements and Kitovs Safe Harbor Statement

Certain statements in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Registration Statement on Form F-1 filed with the  U.S. Securities and Exchange Commission (the “SEC) (file number 333-211477), in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under Risk Factors in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, http://www.sec.gov.

Contact:
Simcha Rock
Chief Financial Officer
+972-3-9333121 ext. #105
simcha@kitovpharma.com

Bob Yedid
Managing Director
LifeSci Advisors, LLC
+1-646-597-6989
bob@LifeSciAdvisors.com

Tuesday, September 27th, 2016 Uncategorized Comments Off on $KTOV Successful Results #KIT302 Pharmacokinetic Bioequivalence Study

$DRIO Launches New Digital Platform and #OnlineStore in #Canada

Collaborative partnership with A&D Medical and Diabetes Express to expand distribution of Dario in Canada with online platform for sales and prescription processing

BOSTON, Sept. 27, 2016  — DarioHealth Corp. (NASDAQ:DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Smart Diabetes Management Solution, today announced the launch of an online store in Canada. This is in collaboration with A&D Medical, a global leader in connected health and biometric measurement devices and services, and Bayshore Specialty Rx Ltd.’s online pharmacy Diabetes Express.

While Dario is widely accepted under reimbursement in Canada, this partnership with Bayshore Specialty Rx Ltd. allows for a complete online experience for Dario products and supplies. The full service provided by Diabetes Express, a division of Bayshore Specialty Rx Ltd., includes all handling of the prescription and interaction with the insurers. The new online store’s URL will be http://mydario.ca and be operated in collaboration with DarioHealth, Diabetes Express and A&D. DarioHealth is responsible for the digital marketing and Diabetes Express will handle reimbursement and the prescription process.

“We are thrilled with these partnership agreements and our launch of a Canadian online store as an implementation of our strategy to make the life of people with diabetes easier,” said Erez Raphael, DarioHealth’s Chairman and Chief Executive Officer. “Our team at DarioHealth has developed strong direct digital marketing capabilities and combined with our partners’ complete end-to-end digital pharmacy capabilities, including prescription processing and reimbursement, we will offer a complete and robust offering to the diabetes population in Canada.”

Aleksandra Filipovic, Director of Bayshore Diabetes, stated, “I am confident that the combination of a highly-digital and engaging product like Dario and our online direct to consumer platform will provide an extremely valuable experience for patients with diabetes.”

Terry Duesterhoeft, President and CEO of A&D, stated, “Dario is one of the featured products in our Canadian portfolio and we look forward to boosting Dario sales through our digital pharmacy platform.”

About A&D Medical

Since 1977, A&D Medical has manufactured and distributed a full line of advanced biometric monitoring solutions including blood pressure monitors, weight scales, activity monitors, and other health monitoring devices for consumer and professional use. A&D Medical is the worldwide leader in connected health and biometric measurement devices and services for consumer wellness and chronic condition management, marketing under the A&D brand globally and also the LifeSource brand in North America. A&D Medical is a division of A&D Company, a global manufacturer of measurement equipment, with operations in Asia, Europe, Australia, Russia, North America, and South America.

For general information about A&D Medical, please visit www.andonline.com.

About Bayshore Specialty Rx Ltd.

A division of Bayshore HealthCare, a premier healthcare provider and a proudly Canadian company since 1966, Bayshore Specialty Rx Ltd., provides a wide-range of patient support programs that include services such as data management support, specialty nursing, specialty pharmacy, reimbursement services and call centre. Bayshore operates more than 45 infusion clinics and pharmacies across the country with the goal to improve patient outcomes through integrated support of complex therapies and community services.

Diabetes Express, A Division of Bayshore Specialty Rx Ltd., is the diabetes focused business unit which works directly with manufacturers, diabetes education clinics and patients to provide the best diabetes product support, access and information within every province in Canada.

About DarioHealth Corp.

DarioHealth is a leader in digital health self-management solutions. DarioHealth delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. The Dario™ Smart Diabetes Management Solution is a platform for diabetes management that combines the Dario Blood Glucose Monitoring System all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.  Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium.  For more information, visit http://mydario.investorroom.com/

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements.  For example, when the Company describes the impact on sales and distribution from the new online store, and says that U.S. sales are expected to have a significant impact on the Company’s revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
Shmuel@mydario.com
+1-800-896-9062

DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331

Tuesday, September 27th, 2016 Uncategorized Comments Off on $DRIO Launches New Digital Platform and #OnlineStore in #Canada